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Abstract 
We report here the case of a 71 year-old male, former smoker of 60 pack-years, with an history of 
congenital hypogammaglobulinemia associated to recurrent fever and persistent productive cough, 
treated with immunoglobulin G (IgG) replacement therapy. On the last 3 years he was followed by 
our outpatient clinic for chronic respiratory failure (treated with long-term oxygen therapy) 
secondary to diffuse bilateral bronchiectasis and pulmonary panacinar emphysema. The patient did 
not follow our influenza and pneumococcal vaccinations recommendations. The patient died after 3 
years of follow-up.We report here an unusual case in an adult of diffuse and bilateral bronchiectasis 
secondary to congenital hypogammaglobulinemia. 
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Introduction 
The bronchiectasis are permanent dilatation of bronchi (1). The cause of bronchiectasis is 
unknown up to 50% of cases, whereas immune defects, such as congenital 
hypogammaglobulinemia, are uncommon cause of bronchiectasis in the adult (2,3).  
Case presentation 
A 71 year-old male, past farmer, former smoker from 22 years of 60 pack-years, with an 
history of congenital hypogammaglobulinemia associated to recurrent fever and persistent 
productive cough, treated with immunoglobulin G (IgG) replacement therapy. On the last 3 
years he was followed by our outpatient clinic for chronic respiratory failure (treated with 
long-term oxygen therapy) secondary to diffuse and bilateral bronchiectasis and pulmonary 
emphysema. His family history was negative for respiratory and immune system diseases. 
He was under regular oral treatment with lamotrigine (100 mg once/daily) for generalized 
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epilepsy, irbesartan (300 mg once/daily) for systemic arterial hypertension, esomeprazole 
(20 mg once/daily) for erosive gastritis and mesalazine (800 mg once/daily) for ulcerative 
colitis.  At the last outpatient visit his vital signs were: systemic blood pressure 130/75 
mmHg, pulse frequency 84/min rhythmic, body axillary temperature 36,5°C, oxygen 
saturation value of 90% (when breathing room air) with a respiratory rate of 16 breaths per 
minute.  His height was 167 cm, weight of 42 Kg with a body mass index of 15 Kg/m
2
. 
Physical examination of the chest revealed only the presence of a diffuse reduced intensity 
of the vescicular breath sound. Not other physical signs outside the chest were phatological. 
An arterial blood gas analysis (performed when the patient was breathing room air) showed: 
pH of 7.41, an arterial partial pressure of oxygen of 46 mmHg, an arterial partial pressure of 
carbon dioxide of 48 mmHg. Routine blood laboratory tests were normal. The last 
concentration of the serum immunoglobulin assay (measured one month after the last 
intravenous administration of IgG) is reported in table 1.  
Table 1. Serum immunoglobulins concentration one month after last administration 
of immunoglobulin. 
Serum immunoglobulins concentration normal values  
Immunoglobulin A  
Immunoglobulin G  
Immunoglobulin M  
70-400 mg/dL 
700-1600 mg/dL 
40-230 mg/dL 
 
5 mg/dL 
459 mg/dL 
4 mg/dL 
 
 
Figure 1. (A,B) Computed tomography scan of chest showing diffuse bronchiectasis and pulmonary emphysema  
 
 
 
The last computed tomography scan of the chest showed the presence of diffuse and 
bilateral bronchiectasis together pulmonary panacinar emphysema (figures 1 and 2).  
The temporal variation of the forced expiratory volume in the one second are showed in Figure 3. 
The patient never followed our influenza and pneumococcal vaccination recommendations. 
During the 3 years of follow-up he had frequent (three in the last year) exacerbations of 
A 
B 
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bronchiectasis with a progressive decline of the clinical condition until the death  
Figure 2. 3D reconstruction of computed tomography scan of the chest. 
 
Discussion 
Primary hypogammaglobulinemias are disorders of heterogeneous etiology, characterized by low 
levels of serum immunoglobulins and impaired antibody production with increased susceptibility 
to pulmonary infections that often result in the onset of diffuse and bilateral bronchiectasis (3). 
The immunoglobulin G replacement therapy reduces the frequency of infectious episodes and 
prevents further destruction of the airways (1). The presence of bronchiectasis at the time of 
diagnosis is predictive of poor prognosis (4), and unfortunately the progression of the 
bronchiectasis occurs despite an adequate immunoglobulin replacement therapy (3). Indipendent 
predictors of mortality to the patients with bronchietasis include older age, low forced expiratory 
volume in the 1st second, low body mass index, previous hospitalizations, and > three 
exacerbations in the previous year (5).  
The long-term management of patients with diffuse bronchiectasis is difficulty because outside of 
seasonal influenza and pneumococcal vaccination, there is little evidence that all the available drug 
treatment may significantly change the natural history (including prevention of exacerbations and 
hospital admissions) without causing significant side effects (6). The long-term oxygen therapy is often 
prescribed to these patients for it’s effect on dyspnea but does not increase survival, at the opposite of 
what observed in chronic obstructive pulmonary disease (7). The long-term prognosis of the patients 
with bronchiectasis is poor and is influenced by the secondary cause (8). 
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Figure 3. Variations of pre- bronchodilator forced expiratory volume in one second (FEV1) over the years. 
 
 
Conclusion  
We report here an unusual case in an adult of diffuse and bilateral bronchiectasis secondary to 
congenital hypogammaglobulinemia. 
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